NR2B subtype-selective NMDA receptor antagonists: 2001-2004

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 4, 2005, Pages 389-407

  McCauley, John A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CNS; Glutamate; Ion channel; NMDA; NR2B antagonists

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMINOCYCLOHEXANE DERIVATIVE; BESONPRODIL; CI 1041; CO 101244; CP 283 097; CYCLOHEXANE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; ELIPRODIL; EMD 95885; FIBRINOLYTIC AGENT; HALOPERIDOL; IFENPRODIL; IONOTROPIC RECEPTOR ANTAGONIST; KETAMINE; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUTROPHIL INHIBITORY FACTOR; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE DERIVATIVE; PHENOL DERIVATIVE; PIPERIDINE DERIVATIVE; PRAZOSIN; RECEPTOR SUBUNIT; RGH 896; RO 63 1908; RO 67 8867; TRAXOPRODIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; ALZHEIMER DISEASE; BINDING SITE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DYSKINESIA; DYSPHORIA; EPILEPSY; HALLUCINATION; HEARING LOSS; HEART DISEASE; HUMAN; MIGRAINE; NEUROPATHIC PAIN; NONHUMAN; PATENT; RECEPTOR BINDING; REVIEW; VISUAL IMPAIRMENT;

EID: 18144428396     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.4.389     Document Type: Review

References (99)

1. MADDEN DR: The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. (2002) 3(2):91-101.
2. DINGLEDINE R, BORGES K, BOWIE D, TRAYNELIS SF: The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51(1):7-61.
3. LYNCH DR, GUTTMAN RP: NMDA receptor pharmacology: perspectives from molecular biology. Curr. Drug Targets (2001) 2(3):215-231.
4. PARSONS CG, DANYSZ W, QUACK G: Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. (1998) 11(9):523-579.
5. PALMER GC: Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr. Drug Targets (2001) 2(3):241-271.
6. LE DA, LIPTON SA: Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging (2001) 18(10):717-724.
7. SMITH PF: Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Invest. Drugs (2003) 4(7):826-832.
8. HOCKING G, COUSINS MJ: Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. (2003) 97(6):1730-1739.
9. FERRIS SH: Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin. Pharmacother. (2003) 4(12):2305-2313.
10. LIPTON SA, CHEN H-SV: Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. (2004) 11(1):18-20.
11. SUGIHARA H, MORIYOSHI K, ISHII T, MASU M, NAKANISHI S: Structures and properties of seven isoforms of NMDA receptor generated by alternative splicing. Biochem. Biophys. Res. Commun. (1992) 185(3):826-832.
12. CULL-CANDY S, BRICKLEY S, FARRANT M: NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. (2001) 11(3):327-335.
13. CHATTERTON JE, AWOBULUYI M, PREMKUMAR LS et al.: Excitatory glycine receptor containing the NR3 family of NMDA receptor subunits. Nature (2002) 415(6873):793-798.
14. MONYER H, BURNASHEV N, LAURIE DJ, SAKMANN B, SEEBURG PH: Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron (1994) 12(3):529-540.
15. WILLIAMS K: Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanism at recombinant heteromeric receptors. Mol. Pharmacol. (1993) 44(4):851-859.
16. BOYCE S, WYATT A, WEBB JK et al.: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. Neuropharmacology (1999) 38(5):611-623.
17. LOFTIS JM, JANOWSKY A: The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical applications. Pharmacol. Therap. (2003) 97(1):55-85.
18. MALHERBE P, MUTEL V, BROGER C et al.: Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the Ro 25-6981 binding pocket. J. Pharmacol Exp. Ther. (2003) 307(3):897-905.
19. GIBB AJ: NMDA receptor subunit gating-uncovered. Trends Neurosci. (2004) 27(1):7-10.
20. BANKE TG, TRAYNELIS SF: Activation of NR1/NR2B NMDA receptors. Nat. Neurosci. (2003) 6(2):144-152.
21. CHAZOT PL, LAWRENCE S, THOMPSON CL: Studies on the subtype selectivity of CP-101,606: evidence for two classes of NR2B-selective NMDA receptor antagonists. Neuropharmacology (2002) 42(3):319-324.
22. CHENARD BL, BORDNER J, BUTLER TW et al.: (1S,2 S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino) -1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J. Med. Chem. (1995) 38(16):3138-3145.
23. FISCHER G, MUTEL V, TRUBE G et al.: Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. (1997) 283(3):1285-1292.
24. TANG Y-P, SHIMIZU E, DUBE GR et al.: Genetic enhancement of learning and memory in mice. Nature (1999) 401(6748):63-69.
25. DOYLE KM, FEERICK S, KIRKBY DL, EDDLESTON A, HIGGINS GA: Comparison of various N-methyl-D-aspartate receptor antagonists in a model of short-term memory and on overt behavior. Behav. Pharmacol. (1998) 9(8):671-681.
26. GUSCOTT MR, CLARKE HF, MURRAY F, GRIMWOOD S, BRISTOW LJ, HUTSON PH: The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur. J. Pharmacol. (2003) 476(3):193-199.
27. GILL R, ALANINE A, BOURSON B et al.: Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl) -piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J. Pharmacol. Exp. Ther. (2002) 302(3):940-948.
28. HIGGINS GA, BALLARD TM, HUWYLER J, KEMP JA, GILL R: Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology (2003) 44(3):324-341.
29. ZHOU Z-L, CAI SX, WHITTEMORE ER et al.: 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4- (4-methylbenzyl)piperidine: A novel, potent, and selective NR1/2B NMDA receptor antagonist. J. Med. Chem. (1999) 42(15):2993-3000.
30. PARSONS CG: NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. (2001) 429(1-3):71-78.
31. CHIZH BA: Novel approaches to targeting glutamate receptors for the treatment of chronic pain: review article. Amino Acids (2002) 23(1-3):169-176.
32. PETRENKO AB, YAMAKURA T, BABA H, SHIMOJI K: The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review: Anesth. Analg. (2003) 97(4):1108-1116.
33. GURWITZ D, WEIZMAN A: The NR2B subunit of glutamate receptors as a potential target for relieving chronic pain: prospects and concerns. Drug Discov. Today (2002) 7(7):403-406.
34. TANIGUCHI K, SHINJO K, MIZUTANI M et al.: Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. (1997) 122(5):809-812.
35. CHIZH BA, HEADLEY PM, TZSCHENTKE TM: NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol. Sci. (2001) 22(12):636-642.
36. KEMP JA, MCKERNAN RM: NMDA receptor pathways as drug targets. Nat. Neurosci. (2002) 5(suppl.):1039-1042.
37. CHAZOT PL: The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. (2004) 11(3):389-396.
38. NASH JE, HILL MP, BROTCHIE JM: Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Exp. Neurol. (1999) 155(1):42-48.
39. MARINO M, VALENTI O, CONN PJ: Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging (2003) 20(5):377-397.
40. NASH JE, FOX SH, HENRY B et al.: Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. (2000) 165(1):136-142.
41. STEECE-COLLIER K, CHAMBERS LK, JAW-TSAI SS, MENNITI, FS, GREENMYRE JT: Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Exp. Neurol. (2000) 163(1):239-243.
42. LÖSCHMANN P-A, DE GROOTE C, SMITH L et al.: Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp. Neurol. (2004) 187(1):86-93.
43. NASH JE, RAVENSCROFT P, MCGUIRE S, CROSSMAN AR, MENNITI FS, BROTCHIE JM: The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. (2004) 188(2):471-479.
44. WESSEL RH, AHMED SM, MENNITI FS, DUNBAR GL, CHASE TN, OH JD: NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemiparkinsonian rats. Neuropharmacology (2004) 47(2):184-194.
45. HADJ TAHAR A, GRÉGOIRE L, DARRÉ A, BÉLANGER N, MELTZER L, BÉDARD PJ: Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. (2004) 15(2):171-176.
46. BLANCHET PJ, KONITSIOTIS S, WHITTEMORE ER, ZHOU ZL, WOODWARD RM, CHASE TN: Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. (1999) 290(3):1034-1040.
47. BLANCHET PJ, CALON F, MORISSETTE M et al.: Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Rel. Dis. (2004) 10(5):297-304.
48. BARTON ME, WHITE HS: The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res. (2004) 59(1):1-12.
49. KOHL BK, DANNHARDT G: The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr. Med. Chem. (2001) 8(11):1275-1289.
50. NAGY J, HORVÁTH C, FARKAS S, KOLOK S, SZOMBATHELYI Z: NR2B subunit selective NMDA antagonists inhibit neurotoxic effect of alcohol-withdrawal in primary cultures of rat cortical neurones. Neurochem. Int. (2004) 44(1):17-23.
51. NAGY J: Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? Invest. Drugs J. (2004) 7(4):339-350.
52. ALBERCH J, CANALS JM, PÉREZ-NAVARRO E: Therapeutic strategies in Huntington's disease. Expert Opin. Ther. Patents (2003) 13(4):449-465.
53. WOOD PL, HAWKINSON JE: N-methyl-D-aspartate antagonists for stroke and head trauma. Expert Opin. Investig. Drugs (1997) 6(4):389-397.
54. PEDERSEN V, SCHMIDT WJ: The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs. Neurotox. Res. (2000) 2(2-3):179-204.
55. WILLIAMS AJ, DAVE JR, LU XM, LING G, TORTELLA FC: Selective NR2B NMDA receptor antagonists are protective against staurosporine-induced apoptosis. Eur. J. Pharmacol. (2002) 452(1):135-136.
56. HYND MR, SCOTT HL, DODD PR: Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer's disease. J. Neurochem. (2004) 90(4):913-919.
57. CHOI DW: Exploratory clinical testing of neuroscience drugs. Nat. Neurosci. (2002) 5(suppl.):1023-1025.
58. MERCHANT RE, BULLOCK MR, CARMACK CA et al.: A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. NY Acad. Sci. (1999) 890:42-50.
59. BULLOCK MR, MERCHANT RE, CARMACK CA et al.: An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann. NY Acad. Sci. (1999) 890:51-58.
60. SANG CN, WEAVER JJ, JINGA L, WOUDEN J, SALTARELLI MD: The NR2B subunit-selective NMDA receptor antagonist, CP-101,606, reduces spontaneous pain intensity in patients with central and peripheral neuropathic pain. Program No. 814.9. 2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003) online.
61. CHENARD BL, MENNITI FS: Antagonists selective for NMDA receptors containing the NR2B subunit. Curr. Pharm. Des. (1999) 5(5):381-404.
62. NIKAM SS, MELTZER LT: NR2B selective NMDA receptor antagonists. Curr. Pharm. Des. (2002) 8(10):845-855.
63. 3H]Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. (1998) 70(5):2147-2155.
64. 1-adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J. Med. Chem. (1991) 34(10):3085-3090.
65. MENNITI F, CHENARD B, COLLINS M, DUCAT M, SHALABY I, WHITE F: CP-101,606, a potent neuroprotectant selective for forebrain neurons. Eur. J. Pharmacol. (1997) 331(2/3):117-126.
66. BUTLER TW, BLAKE JF, BORDNER J et al.: (3R,4S)-3-[4-(4-Fluorophenyl)-4-hydroxypiperidin- 1-yl]chroman-4,7-diol: a conformationally restricted analog of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy- 4-phenylpiperidino)-propanol. J. Med. Chem. (1998) 41(7):1172-1184.
67. WHITTEMORE ER, ILYIN VI, KONKOY CS, WOODWARD RM: Subtype-selective antagonism of NMDA receptors by nylidrin. Eur. J. Pharmacol. (1997) 337(2/3):197-208.
68. TAMIZ AP, WHITTEMORE ER, ZHOU Z-L et al.: Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J. Med. Chem. (1998) 41(18):3499-3506.
69. GUZIKOWSKI AP, TAMIZ AP, ACOSTA-BURRUEL M et al.: Synthesis of N-substituted 4-(4-hydroxyphenyl)piperidines, 4-(4-hydroxybenzyl)piperidines, and (±)-3-(4-hydroxyphenyl)pyrrolidines: selective antagonists at the 1A/2B NMDA receptor subtype. J. Med. Chem. (2000) 43(5):984-994.
70. KEW JNC, TRUBE G, KEMP JA: State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist. Br. J. Pharmacol. (1998) 123(3):463-472.
71. CHAZOT PL: CP-101606 (Pfizer Inc). Curr. Opin. Invest. Drugs (2000) 1(3):370-374.
72. MENNITI FS, SHAH AK, WILLIAMS SA, WILNER KD, WHITE WF, CHENARD BL: CP-101,606: an NR2B-selective NMDA receptor antagonist. CNS Drug Rev. (1998) 4(4):307-322.
73. PINARD E, ALANINE A, BOURSON A et al.: Discovery of (R)-1-[2-hydroxy-3-(4-hydroxy-phenyl)-propyl]-4- (4-methyl-benzyl)-piperidin-4-ol: A novel NR1/2B subtype selective NMDA receptor antagonist. Bioorg. Med. Chem. Lett. (2001) 11(16):2173-2176.
74. SCALONE M, WALDMEIER P: Efficient enantioselective synthesis of the NMDA 2B receptor antagonist Ro 67-8867. Org. Proc. Res. Dev. (2003) 7(3):418-425.
75. BORZA I, KOLOK S, GERE A et al.: Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(21):3859-3861.
76. TAMIZ AP, WHITTEMORE ER, WOODWARD RM, UPASANI RB, KEANA JFW: Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-methyl-D-aspartate (NMDA) receptors. Bioorg. Med. Chem. Lett. (1999) 9(11):1619-1624.
77. FARKAS S, HORVATH C, NAGY J et al.: RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. Program No. 382.8. 2003 Abstract Viewer/Itinerary Planner. Washington, DC. Society for Neuroscience (2003) online.
78. MCCAULEY JA, THEBERGE CR, ROMANO JJ et al.: NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J. Med. Chem. (2004) 47(8):2089-2096.
79. LEIBROCK J, PRÜCHER H, RAUTENBERG W: EMD 95885, a new eliprodil analog with higher affinity for the N-methyl-D-aspartate (NMDA) receptor. Pharmazie (1997) 52(6):479-480.
80. WRIGHT JL, GREGORY TF, BIGGE CF et al.: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines. J. Med. Chem. (1999) 42(13):2469-2477.
81. WRIGHT JL, GREGORY TF, BOXER PA et al.: Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists. Bioorg. Med. Chem. Lett. (1999) 9(19):2815-2818.
82. WRIGHT JL, GREGORY TF, KESTEN SR et al.: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines. J. Med. Chem. (2000) 43(18):3408-3419.
83. KORNBERG BE, NIKAM SS, WRIGHT JL et al.: Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues. Bioorg. Med. Chem. Lett. (2004) 14(5):1213-1216.
84. SCHELKUN RM, YUEN P-W, SERPA K et al.: Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. J. Med. Chem. (2000) 43(9):1892-1897.
85. GREGORY TF, WRIGHT JL, WISE LD et al.: Parallel synthesis of a series of subtype-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10(6):527-529.
86. BARTA-SZALAI G, BORZA I, BOZÓ E et al.: Oxamides as novel NR2B selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14(15):3953-3956.
87. PRÜCHER H, GOTTSCHLICH R, HASSE A, STOHER M, SEYFRIED C: (5S)-3-Aryl-5-(1-piperidinylmethyl)-2-oxazolidinones, a new class of potential neuroleptics with a high affinity for sigma receptors. Bioorg. Med. Chem. Lett. (1992) 2(2):165-170.
88. WHITTEMORE ER, ILYIN VI: WOODWARD RM: Antagonism of N-methyl-D-aspartate receptors by σ-site ligands: potency, subtype-selectivity and mechanisms of inhibition. J. Pharmacol. Exp. Ther. (1997) 282(1):326-338.
89. BÜTTELMANN B, ALANINE A, BOURSON A et al.: 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(5):829-832.
90. BÜTTELMANN B, ALANINE A, BOURSON A et al.: 4-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(10):1759-1762.
91. PINARD E, ALANINE A, BOURSON A et al.: 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2002) 12(18):2615-2619.
92. CURTIS NR, DIGGLE HJ, KULAGOWSKI JJ et al.: Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(4):693-696.
93. TAMIZ AP, WHITTEMORE ER, SCHELKUN RM et al.: N-(4-Hydroxyphenethyl)-4-chlorocinnamamide: a novel antagonist at the 1A/2B NMDA receptor subtype. Bioorg. Med. Chem. Lett. (1998) 8(2):199-200.
94. TAMIZ AP, CAI SX, ZHOU Z-L et al.: Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists. J. Med. Chem. (1999) 42(17):3412-3420.
95. MCCAULEY JA, THEBERGE CR, LIVERTON NJ: Chemoselective reactions of amidines: selective formation of iminopyrimidine regioisomers. Org. Lett. (2000) 2(21):3389-3391.
96. CLAIBORNE CF, MCCAULEY JA, LIBBY BE et al.: Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(4):697-700.
97. BEDNAR B, CUNNINGHAM ME, KISS L et al.: Kinetic characterization of novel NR2B antagonists using fluorescence detection of calcium flux. J. Neurosci. Meth. (2004) 137(2):247-255.
98. ALANINE A, BOURSON A, BÜTTELMANN Bet al.: 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (2003) 13(19):3155-3159.
99. DONEYAN SD, MCCABE RT: Conantokin G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol. Pharmacol. (2000) 58(3):614-623.